Table 4.

Univariate and multivariate analysis of risk factors predicting venous and arterial thrombotic events among NSCLC patients with different molecular drivers

Variable	Arterial thrombosis				Venous thrombosis
	Univariate analysis		Multivariate analysis		Univariate analysis		Multivariate analysis
	HR (95% CI)	P value	HR (95% CI)	P value	HR (95% CI)	P value	HR (95% CI)	P value
ROS1 versus ALK	1.749 (0.20-14.99)	0.61	1.669 (0.19-14.46)	0.64	0.991 (0.50-1.98)	0.98	1.036 (0.52-2.07)	0.92
ROS1 versus EGFR	4.205 (0.56-31.78)	0.16	3.745 (0.47-30.04)	0.21	0.505 (0.24-1.05)	0.07	0.548 (0.25-1.18)	0.13
EGFR versus ALK	0.42 (0.15-1.14)	0.09	—	—	1.96 (1.12-3.43)	0.02	—	—
Age (years, ≦60 versus >60)	0.294 (0.12-0.75)	0.01a	0.376 (0.14-1.02)	0.05a	0.817 (0.49-1.36)	0.44	1.022 (0.59-1.77)	0.94
Sex (male versus female)	1.388 (0.60-3.22)	0.44	1.827 (0.61-4.69)	0.21	0.823 (0.49-1.39)	0.47	0.600 (0.32-1.13)	0.11
Smoking (smoker versus nonsmoker)	0.804 (0.27-2.38)	0.69	0.679 (0.20-2.27)	0.53	1.111 (0.62-1.99)	0.72	1.343 (0.67-2.68)	0.40
Stage (per one stage increase)	2.908 (1.07-7.90)	0.04a	2.825 (1.10-7.26)	0.03a	1.410 (1.02-1.94)	0.04a	1.373 (0.98-1.92)	0.06

ALK, anaplastic lymphoma kinase; CI, confidence interval; EGFR, epidermal growth factor receptor; HR, hazard ratio; NSCLC, non-small-cell lung cancer.

^aP < 0.05.